This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Has Aptinyx Inc. (APTX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aptinyx Inc. (APTX) and Doximity (DOCS) have performed compared to their sector so far this year.
Ensign Group (ENSG) Up 9.9% in 3 Months: More Room to Grow?
by Zacks Equity Research
Ensign Group (ENSG) expects annual revenues for 2022 in the band of $2.93-$2.98 billion, whose midpoint signals a 12.4% rise from the 2021 reported figure.
Here's How Mednax (MD) Can Gain By Adopting the Pediatrix Brand
by Zacks Equity Research
Mednax (MD) bringing some of its operations under the Pediatrix brand is expected to collectively promote its wide range of healthcare services.
How Much Upside is Left in Doximity (DOCS)? Wall Street Analysts Think 32%
by Zacks Equity Research
The mean of analysts' price targets for Doximity (DOCS) points to a 32.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
OCDX vs. DOCS: Which Stock Is the Better Value Option?
by Zacks Equity Research
OCDX vs. DOCS: Which Stock Is the Better Value Option?
Teladoc (TDOC) Q4 Loss Narrows on Higher Visits, Memberships
by Zacks Equity Research
Teladoc (TDOC) projects 2022 total visits in the band of 18.5-20 million, indicating an uptick from the 2021 level of 15.4 million.
Wall Street Analysts Believe Doximity (DOCS) Could Rally 36%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 36.2% in Doximity (DOCS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Has Aziyo Biologics, Inc. (AZYO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aziyo Biologics, Inc. (AZYO) and Doximity (DOCS) have performed compared to their sector so far this year.
Doximity (DOCS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Doximity's (DOCS) fiscal third-quarter results are likely to reflect growth in its telehealth platform and robust net revenue retention rate.
Doximity (DOCS) Stock Moves -1.87%: What You Should Know
by Zacks Equity Research
Doximity (DOCS) closed the most recent trading day at $45.70, moving -1.87% from the previous trading session.
Doximity (DOCS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Doximity (DOCS) closed at $42.47 in the latest trading session, marking a -0.38% move from the prior day.
Doximity (DOCS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Doximity (DOCS) closed at $43.32, marking a +1.14% move from the previous day.
Doximity (DOCS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Doximity (DOCS) closed at $47.64 in the latest trading session, marking a +1.56% move from the prior day.
Doximity (DOCS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Doximity (DOCS) closed at $51.34, marking a -0.43% move from the previous day.
TVTY or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
TVTY vs. DOCS: Which Stock Is the Better Value Option?
Walgreens (WBA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Faster adoption of digital health and recent partnerships are expected to have contributed to Walgreens' (WBA) first-quarter performance.
Doximity (DOCS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Doximity (DOCS) closed at $50.08 in the latest trading session, marking a +1.54% move from the prior day.
Why Seasoned Investors are Retaining Acadia (ACHC) Stock
by Zacks Equity Research
Acadia Healthcare's (ACHC) buyouts are helping the company to add facilities, beds and hospitals to its network and contributing to its top line.
Should You Buy Doximity (DOCS) Ahead of Earnings?
by Zacks Equity Research
Doximity (DOCS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
The Zacks Analyst Blog Highlights: D.R. Horton, RingCentral, Doximity, Disney and Affirm Holdings
by Zacks Equity Research
The Zacks Analyst Blog Highlights: D.R. Horton, RingCentral, Doximity, Disney and Affirm Holdings
OCDX or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
OCDX vs. DOCS: Which Stock Is the Better Value Option?
5 Large-Cap Stocks Likely to Win Big on Earnings Next Week
by Nalak Das
Five large-cap (market capital > $10 billion) stocks will report earnings results next week. These are: DHI, RNG, DOCS, DIS and AFRM.
What's in the Cards for Doximity (DOCS) in Q2 Earnings?
by Zacks Equity Research
Doximity's (DOCS) products like Doximity Dialer and Residency Navigator have been in focus and we expect both to have generated significant revenues during the fiscal second quarter.
DiDi Global (DIDI) Goes Public: Here's What You Need to Know
by Maharathi Basu
DiDi Global (DIDI) is currently trading at 17.1% above its IPO price.